DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Neuland Laboratories Limited (NEULANDLAB) share price today?

Neuland Laboratories Limited (NEULANDLAB) is trading at ₹20,135 on the NSE, down 0.32% on the day. Source: DocStoX.

What is the PE ratio of Neuland Laboratories Limited?

Neuland Laboratories Limited has a price-to-earnings (PE) ratio of 71.0 in the Healthcare sector.

What is the market capitalisation of Neuland Laboratories Limited?

Neuland Laboratories Limited has a market capitalisation of approximately ₹25,275 crore.

Is Neuland Laboratories Limited a profitable company?

Neuland Laboratories Limited generates a return on equity of 19.4% with a net profit margin of 18.0%. That is a strong return on shareholder capital.

What is the 52-week high and low of NEULANDLAB?

Neuland Laboratories Limited (NEULANDLAB) has traded between ₹11,500 and ₹24,225 over the past 52 weeks, against a current price of ₹20,135.

Does Neuland Laboratories Limited pay a dividend?

Yes. Neuland Laboratories Limited currently offers a dividend yield of 0.14%. Dividend payments depend on the board's declaration each year.

Neuland Laboratories Limited

₹20,135.00▼ -65.00 (-0.32%)

NEULANDLAB·NSE·Healthcare

Market Cap

25274.50 Cr

PE Ratio

70.97

Volume

45,292

Day High - Low

20400.00 - 19805.00

52W High-Low

24225.00 - 11500.00

₹20,135.00▼ -65.00 (-0.32%)

Market Cap25274.50 Cr

PE Ratio70.97

Volume45,292

Day High - Low20400.00 - 19805.00

52W High-Low24225.00 - 11500.00

Neuland Laboratories Limited (NEULANDLAB): company summary

The company's business is improving, with annual revenue rising 37.0% and net profit growing 40.0% year-over-year.

Neuland Laboratories Limited (NEULANDLAB) is a mid-cap Healthcare company valued at ₹25,275 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Neuland Laboratories Limited last traded at ₹20,135, modestly down 0.32% on the day.
Recent developments: On 2026-07-24, the company announced a dividend of ₹34.00 per share, ex-date. Promoter holding remained at 32.62% as of 2026-06-30, with 2.29% of promoter shares pledged. Foreign institutional holding increased by 0.62 points, and domestic institutional holding rose by 0.67 points in the quarter.
Financial performance: The company's business is improving, with annual revenue rising 37.0% and net profit growing 40.0% year-over-year. The latest quarter saw revenue surge 119.0% compared to the same quarter a year earlier, while net profit jumped 954.8%, reflecting strong growth in both top and bottom lines.
Valuation multiples: The stock trades at 71.0 times earnings, a premium to the Healthcare median of 32.0, 16.30 times book value. It yields 0.1%.
Things to watch: The stock is 13.8% below its 52-week high, and the latest quarter's net profit growth was exceptionally high compared to prior periods, which may not be sustainable. Promoter shares pledged could indicate liquidity pressures or strategic realignment.
Where it stands: The company has delivered strong revenue and profit growth, with the latest quarter showing a remarkable increase in net profit. The stock's distance from its 52-week high and the pledged promoter shares are key factors to note as of now.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.8/10

Fair

Fair Value

ROE

19.42%

Strong

P/E

70.97x

Expensive

Debt / Equity

0.16

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 500NIFTY SMALLCAP 250

Day₹19805

₹20400

52W₹11500

₹24225

DocStoX take

Supported by growth (9.1) and risk (8.6), but held back by valuation (0.0). Growth looks strong at 9.1, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.8

/10

Fair

Quality

Excellent

ROE 19.4%

Valuation

Expensive

P/E 71.0×

Growth

Strong

Revenue +16.6% 5Y CAGR

Risk

Low risk

D/E 0.16

Momentum

Strong

68% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹20,135

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹25,275 Cr

52W High / Low

₹24225 / ₹11500

Dividend Yield

0.14%

Promoter Holding

32.26%

EPS (TTM)

₹283.71

Book Value

₹1453.02

Key highlights

Profit compounding 35% a year
Low leverage — D/E 0.16
Profitable in all of the last 5 years
Valuation is weak (0.0/10)
Expensive at 71× earnings

4 Positives2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Neuland Laboratories Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Neuland Laboratories Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Neuland Laboratories Limited with peers

Neuland Laboratories Limited vs Sun Pharmaceutical Industries Limited Neuland Laboratories Limited vs Divi's Laboratories Limited Neuland Laboratories Limited vs Torrent Pharmaceuticals Limited Neuland Laboratories Limited vs Apollo Hospitals Enterprise Limited Neuland Laboratories Limited vs Zydus Lifesciences Limited Neuland Laboratories Limited vs Laurus Labs Limited

Related tools & concepts

Value Neuland Laboratories Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

NEULANDLAB newsLatest coverage & filings Open screenerFilter the whole market